close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

FDA Advisors Declare 'FDA Science and Mission at Risk'

Broad-ranging Report Concludes that Increased Resources Are An Essential First Step

WASHINGTON, Dec. 3 /PRNewswire-USNewswire/ -- The nation's food supply is at risk, as are the regulatory systems that oversee the nation's drug and device supplies, according to a subcommittee of the FDA's Science Board in a report to be presented today. The subcommittee attributes the deficiencies to soaring demands on the FDA; and resources that have not increased in proportion to those demands. They conclude that "this imbalance is imposing a significant risk to the integrity of the food, drug, cosmetic and device regulatory system, and hence the safety of the public."

The result of a year-long review by a distinguished panel of experts, the Subcommittee's 300-page report concludes that the state of FDA's scientific and regulatory programs could not be separated from the lack of resources. It urged funds to support the agency's scientific base, hire a broadly-capable scientific workforce, and build a sophisticated, modern information technology infrastructure.

The FDA Science Board meets from 8 a.m. to 5:30 p.m. on December 03, 2007 at the Gaithersburg, MD Hilton. The Subcommittee is scheduled to present at 12:30 p.m., with discussion continuing until 4 p.m. Its report has been posted on the FDA website in advance of the meeting and is available at: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4329b_02_00_index.html.

Comments on the report:

"Over the last decade, complex scientific advances, globalization and challenging new safety issues have combined to multiply the responsibilities of the FDA. As this new report makes clear: our expectations cannot exceed the resources we give FDA to accomplish its mission. In this regard, more is definitely better."

--Mark McClellan, MD, former FDA commissioner and chairman of the new Reagan-Udall Institute.

"FDA can't improve its science, prepare for the future, or protect American consumers without significant additional resources. Congress is negotiating FDA's FY 2008 (current year) budget right now and can start to fix this critical problem."

--Don Kennedy, PhD, former FDA commissioner and editor-in-chief of Science.

"That FDA needs more resources should be obvious. What makes this report so extraordinary is the qualifications of the individuals who wrote it, the year-long process to put it together, and the depth of analysis that supports its conclusion: FDA's mission is at risk for lack of support for its scientific capabilities."

--Jane Henney, MD, former Commissioner of FDA and Senior Vice President and Provost for Health Affairs, University of Cincinnati.

About the FDA Alliance and the Coalition for a Stronger FDA

In response to the unmet resource needs of the FDA and the threat this poses to America's health, safety and commerce, two organizations were formed in 2006 to educate and advocate about the importance of FDA and the need for better funding. More about each group can be found on their websites: www.StrengthenFDA.org (FDA Alliance) and www.FDACoalition.org (Coalition for a Stronger FDA).

CONTACT: Steven Grossman of the FDA Alliance, +1-301-879-9800,, or Ladd Wiley of Coalition for a Stronger FDA,+1-202-887-4083, info@StrengthenFDA.org lwiley@akingump.com

Web site: http://www.StrengthenFDA.org/http://www.FDACoalition.org//

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...